Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: SKX third-largest global footwear brand at $8.97B FY2024 revenue with 5,000+ stores; 3G Capital announced ~$9.4B take-private in May 2025 competing with Nike and Adidas for athletic and comfort footwear.
Skechers U.S.A., Inc. is a Manhattan Beach, California-based global footwear brand — listed on NYSE (NYSE: SKX) — designing and marketing performance athletic shoes, casual lifestyle sneakers, and work boots for men, women, and children across 180+ countries through 5,000+ company-owned retail stores, department stores, specialty footwear retailers, and e-commerce channels, generating $8.97 billion in net sales in fiscal year 2024 (+12.1% year-over-year) as the third-largest athletic footwear brand globally (behind Nike and Adidas). Founded in 1992 by Robert Greenberg and his son Michael Greenberg, Skechers built its identity on comfort technologies (Air-Cooled Memory Foam, Arch Fit, Relaxed Fit), affordable pricing relative to Nike and Adidas, and broad demographic appeal across kids (Twinkle Toes, S-Lights), adults (walking, running, lifestyle), seniors (Arch Fit Go Walk), and work/safety categories.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.